Abbott to Develop Molecular Test for Tarceva in Collaboration with Genentech, Roche, and OSI | GenomeWeb
NEW YORK (GenomeWeb News) – Illinois-based diagnostics company Abbott has entered into an agreement with Genentech, Roche, and OSI Pharmaceuticals to create a genetic test for determining which lung cancer patients will benefit from erlotinib treatment, the company announced today.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.